title: [Design and activity verification of human parathyroid hormone (1-34) mutant protein].
abstract: Through protein-protein BLAST of homologous sequences in different species in NCBI database and preliminary simulating molecular docking and molecular dynamics by computer software discovery studio 3.1, three amino acids R25K26K27 of natural human parathyroid hormone (1-34) with Q25E26L27 were mutated and the biological activity of the mutant peptide was evaluated. Result showed that: root mean superposition deviation RMSD value between PTH (1-34)-(RKK-QEL) and PTH (1-34) peptide main chain was 2.509 3, indicating that the differences between the two main chain structural conformation was relatively small; the interaction energy between PTH (1-34)-(RKK-QEL) and its receptor protein PTH1R had been enhanced by 7.5% compared to nature PTH (1-34), from -554.083 kcal x mol(-1) to -599.253 kcal x mol(-1); the number of hydrogen bonds was increased from 32 to 38; PTH (1-34)-(RKK-QEL) can significantly stimulate the RANKL gene expression (P < 0.01) while inhibiting the OPG gene expression (P < 0.01) in UAMS-32P cells; in the co-culture system of UAMS-32P cells and mouse primary femur bone marrow cells, PTH (1-34)-(RKK-QEL) stimulated the formation of osteoclasts (P < 0.01) and had a higher biological activity than PTH (1-34) standard reagents.
authors.affiliation: School of Medicine and Pharmaceutics, Jiangnan University, Wuxi 214122, China.
authors.forename: Shuang
authors.initials: S
authors.lastname: Qiu
authors.forename: Yue-Shui
authors.initials: YS
authors.lastname: Jiang
authors.forename: Zhi-Qin
authors.initials: ZQ
authors.lastname: Li
authors.forename: Jian-Yong
authors.initials: JY
authors.lastname: Lei
authors.forename: Yun
authors.initials: Y
authors.lastname: Chen
authors.forename: Jian
authors.initials: J
authors.lastname: Jin
mesh_terms: D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology / Q000378:metabolism; D018920:Coculture Techniques; D051379:Mice; D050505:Mutant Proteins / Q000235:genetics* / Q000494:pharmacology; D009154:Mutation; D010010:Osteoclasts / Q000166:cytology / Q000187:drug effects; D010012:Osteogenesis / Q000187:drug effects; D053244:Osteoprotegerin / Q000235:genetics / Q000378:metabolism*; D053245:RANK Ligand / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D044168:Receptor, Parathyroid Hormone, Type 1 / Q000378:metabolism; D019379:Teriparatide / Q000494:pharmacology*
chemical_list: D050505:Mutant Proteins; D053244:Osteoprotegerin; C473449:PTH1R protein, human; D053245:RANK Ligand; D012333:RNA, Messenger; D044168:Receptor, Parathyroid Hormone, Type 1; D019379:Teriparatide